BR112015008552A2 - material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino - Google Patents
material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalinoInfo
- Publication number
- BR112015008552A2 BR112015008552A2 BR112015008552A BR112015008552A BR112015008552A2 BR 112015008552 A2 BR112015008552 A2 BR 112015008552A2 BR 112015008552 A BR112015008552 A BR 112015008552A BR 112015008552 A BR112015008552 A BR 112015008552A BR 112015008552 A2 BR112015008552 A2 BR 112015008552A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline material
- pharmaceutical composition
- crystalline
- carboxylic acid
- preparation
- Prior art date
Links
- 239000002178 crystalline material Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001346 nilotinib Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1 / 1 resumo âmaterial cristalino, composiãão farmacãutica, e, processo para a preparaãão de um material cristalinoâ a presente invenã§ã£o refere-se a materiais cristalinos compreendendo nilotinibe e um ã¡cido carboxãlico, ã©ster de ã¡cido carboxãlico, amida de ã¡cido carboxãlico ou ã¡cido sulfã´nico como um formador de cocristal, e a composiã§ãµes farmacãªuticas que compreendem os referidos materiais. a invenã§ã£o tambã©m se refere a processos para preparar os referidos materiais cristalinos e a mã©todos de utilizaã§ã£o dessas matã©rias cristalinas para o tratamento de uma condiã§ã£o de doenã§a em que a inibiã§ã£o da tirosina quinase ã© benã©fica.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715865P | 2012-10-19 | 2012-10-19 | |
EP12189264 | 2012-10-19 | ||
EP13167657 | 2013-05-14 | ||
PCT/EP2013/071580 WO2014060449A1 (en) | 2012-10-19 | 2013-10-16 | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015008552A2 true BR112015008552A2 (pt) | 2017-07-04 |
Family
ID=50487597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015008552A BR112015008552A2 (pt) | 2012-10-19 | 2013-10-16 | material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino |
Country Status (11)
Country | Link |
---|---|
US (1) | US9567317B2 (pt) |
EP (1) | EP2909191B1 (pt) |
JP (2) | JP2015534967A (pt) |
KR (1) | KR20150068483A (pt) |
CN (1) | CN104736531A (pt) |
AU (1) | AU2013333953B2 (pt) |
BR (1) | BR112015008552A2 (pt) |
CA (1) | CA2887540A1 (pt) |
MX (1) | MX2015004947A (pt) |
RU (1) | RU2652121C2 (pt) |
WO (1) | WO2014060449A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9173391B2 (en) | 2009-11-06 | 2015-11-03 | Basf Se | Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides |
CA2877030A1 (en) | 2012-06-22 | 2013-12-27 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
ES2598168T3 (es) | 2012-08-06 | 2017-01-25 | Basf Se | Sistema cristalino de múltiples componentes que comprende deferasirox e isonicotinamida y procedimiento para la preparación del mismo |
AU2014295144B2 (en) | 2013-07-25 | 2017-06-15 | Basf Se | Salts of Dasatinib in crystalline form |
US9884857B2 (en) | 2013-07-25 | 2018-02-06 | Basf Se | Salts of dasatinib in amorphous form |
BR112017000304B1 (pt) | 2014-07-08 | 2021-06-29 | BASF Agro B.V. | Processo para a preparação dos compostos de fórmula ii |
CA2964198C (en) | 2014-10-16 | 2023-03-14 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
US9603937B2 (en) * | 2015-03-09 | 2017-03-28 | Theaprin Pharmaceuticals Inc. | Platform drug delivery system utilizing crystal engineering and theanine dissolution |
WO2016180642A1 (en) | 2015-05-08 | 2016-11-17 | BASF Agro B.V. | A process for the preparation of terpinolene epoxide |
EP3294700B1 (en) | 2015-05-08 | 2020-01-29 | BASF Agro B.V. | A process for the preparation of limonene-4-ol |
LT3430004T (lt) | 2016-03-14 | 2020-11-25 | Pliva Hrvatska D.O.O. | Nilotinibo druskų kietosios būsenos formos |
WO2017215929A1 (en) | 2016-06-15 | 2017-12-21 | BASF Agro B.V. | Process for the epoxidation of a tetrasubstituted alkene |
WO2017215928A1 (en) | 2016-06-15 | 2017-12-21 | BASF Agro B.V. | Process for the epoxidation of a tetrasubstituted alkene |
CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
CN113402575B (zh) * | 2021-06-18 | 2022-04-22 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸共晶体的方法 |
CA3224750A1 (en) | 2021-06-19 | 2022-12-22 | Helm Ag | Granulate composition comprising nilotinib |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
JP5069905B2 (ja) * | 2003-01-21 | 2012-11-07 | アプテュイト (ウエスト ラファイエット)、エルエルシー | 新規な共結晶化 |
GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600315A (es) * | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
PL2262793T3 (pl) | 2008-11-05 | 2013-01-31 | Teva Pharma | Formy krystaliczne nilotynibu HCL |
CZ20098A3 (cs) | 2009-01-13 | 2010-07-21 | Zentiva, K.S. | Lékové formy inhibitoru tyrosinových kináz |
WO2011086541A1 (en) * | 2010-01-15 | 2011-07-21 | Generics [Uk] Limited | Novel polymorph of nilotinib monohydrochloride monohydrate |
WO2011163222A1 (en) | 2010-06-21 | 2011-12-29 | Teva Pharmaceutical Industries Ltd. | Nilotinib salts and crystalline forms thereof |
CN102453024B (zh) * | 2010-10-27 | 2014-09-03 | 浙江九洲药业股份有限公司 | 一种尼罗替尼盐酸盐晶型及其制备方法 |
EP2643305A1 (en) | 2010-11-22 | 2013-10-02 | Basf Se | Multicomponent system of rosuvastatin calcium salt and sorbitol |
CA2832343A1 (en) | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
US20140155371A1 (en) | 2011-07-26 | 2014-06-05 | Basf Se | Multicomponent crystalline system of ezetimibe and proline |
PE20141533A1 (es) | 2011-08-30 | 2014-11-14 | Basf Se | Cocristales de cyprodinil y dithianon |
WO2013084130A1 (en) | 2011-12-06 | 2013-06-13 | Basf Se | Multicomponent crystalline system of voriconazole with fumaric acid |
US8796481B2 (en) | 2011-12-30 | 2014-08-05 | Basf Se | Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine |
EP2797937B1 (en) | 2011-12-30 | 2022-08-31 | Basf Se | Non-solvated crystalline form of 6,6'-[[3,3',5,5'-tetrakis(1,1-dimethylethyl)-[1,1'-biphenyl]-2,2'-diyl]bis(oxy)]bis-dibenzo [d,f][1,3,2]-dioxaphosphepine |
US20150065347A1 (en) | 2012-03-29 | 2015-03-05 | Basf Se | Co-crystals of dicamba and a co-crystal former b |
UA116887C2 (uk) | 2012-05-25 | 2018-05-25 | Басф Се | КРИСТАЛІЧНА ФОРМА В 1,5-ДИМЕТИЛ-6-ТІОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ІНІЛ)-3,4-ДИГІДРО-2H-БЕНЗО[b][1,4]ОКСАЗИН-6-ІЛ)-1,3,5-ТРИАЗИНАН-2,4-ДІОНУ |
CA2871315C (en) | 2012-05-25 | 2020-11-03 | Basf Se | Crystalline form a of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione |
MX347429B (es) | 2012-06-15 | 2017-04-26 | Basf Se | Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. |
CA2877030A1 (en) | 2012-06-22 | 2013-12-27 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
ES2598168T3 (es) | 2012-08-06 | 2017-01-25 | Basf Se | Sistema cristalino de múltiples componentes que comprende deferasirox e isonicotinamida y procedimiento para la preparación del mismo |
-
2013
- 2013-10-16 RU RU2015118436A patent/RU2652121C2/ru not_active IP Right Cessation
- 2013-10-16 WO PCT/EP2013/071580 patent/WO2014060449A1/en active Application Filing
- 2013-10-16 KR KR1020157012700A patent/KR20150068483A/ko not_active Application Discontinuation
- 2013-10-16 EP EP13783008.9A patent/EP2909191B1/en not_active Not-in-force
- 2013-10-16 MX MX2015004947A patent/MX2015004947A/es unknown
- 2013-10-16 CA CA2887540A patent/CA2887540A1/en not_active Abandoned
- 2013-10-16 AU AU2013333953A patent/AU2013333953B2/en not_active Ceased
- 2013-10-16 BR BR112015008552A patent/BR112015008552A2/pt not_active IP Right Cessation
- 2013-10-16 US US14/433,147 patent/US9567317B2/en not_active Expired - Fee Related
- 2013-10-16 CN CN201380054044.6A patent/CN104736531A/zh active Pending
- 2013-10-16 JP JP2015537234A patent/JP2015534967A/ja active Pending
-
2018
- 2018-01-31 JP JP2018014833A patent/JP2018065876A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015534967A (ja) | 2015-12-07 |
AU2013333953A1 (en) | 2015-04-30 |
CA2887540A1 (en) | 2014-04-24 |
US9567317B2 (en) | 2017-02-14 |
AU2013333953B2 (en) | 2017-08-31 |
WO2014060449A1 (en) | 2014-04-24 |
CN104736531A (zh) | 2015-06-24 |
RU2015118436A (ru) | 2016-12-10 |
JP2018065876A (ja) | 2018-04-26 |
US20150246901A1 (en) | 2015-09-03 |
RU2652121C2 (ru) | 2018-04-25 |
EP2909191B1 (en) | 2019-03-20 |
KR20150068483A (ko) | 2015-06-19 |
MX2015004947A (es) | 2016-02-22 |
EP2909191A1 (en) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015008552A2 (pt) | material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino | |
BR112012016879A2 (pt) | Derivados de fumarato de acido graxo e seus usos | |
BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
BR112015009376A2 (pt) | ácidos indaniloxidihidrobenzofuranilacéticos | |
ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
BR112012027509A8 (pt) | Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método | |
BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
BR112012010706A2 (pt) | composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio | |
BR112014010576A8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
CL2015003602A1 (es) | Composiciones y métodos para tratar anemia. | |
BR112012012906A2 (pt) | triazolopiridinas | |
UY33241A (es) | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
CR20130264A (es) | Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2 | |
EA201071167A1 (ru) | Стабилизированные олеосомные композиции и способы их получения | |
BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
BR112012022946A2 (pt) | método para proliferar cardiomiócitos usando micro-rna | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |